2.3. Mass Spectrometry-Based Sphingolipidomic Analysis Confirms Dysregulation of S1P Metabolism as the Mechanism Underlying Vemurafenib Resistance in BRAF Mutant Colon Cancer Cells. Here, BRAF is linked to malignant colon neoplasm.